Mitra Biotech, a Bangalore-based research company that develops and provides technologies that personalize cancer treatment has raised $27.4 million in a Series-B funding led by Sequoia India and Washington-based Sands Capital Ventures, with participation from Boston-based RA Capital Management and existing investors Accel Partners and Tata Capital Innovations Fund.
Mitra will use the funds to expand the availability of its CANScript service, which predicts personalized responses to cancer treatments, the company said.
